TH103 Shows Durable Responses in Expanded AMD Trial, 29% Treatment-Free at 6 Months
KLRS has more than doubled off its 52-week low of $2.14.
Summary
Kalaris reported expanded Phase 1a data for TH103 in neovascular AMD, showing durable vision improvements and a clean safety profile at the 2.5 mg dose. In 17 treatment-naive patients, 29% needed no retreatment over six months after a single injection, and 41% went at least four months before first retreatment. No intraocular inflammation occurred at the 2.5 mg dose using an improved manufacturing process. The data also showed vision gains and reduced plasma exposure. These results strengthen the case for TH103 as a potential best-in-class anti-VEGF therapy with extended durability. The ongoing Phase 1b/2 multiple-dose trial is enrolling, with initial data expected in the first half of 2027.
At the time of this announcement, KLRS was trading at $4.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $100.6M. The 52-week trading range was $2.14 to $11.88. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.